[go: up one dir, main page]

EE9900210A - Heptapeptiid oksütotsiini analoogid - Google Patents

Heptapeptiid oksütotsiini analoogid

Info

Publication number
EE9900210A
EE9900210A EEP199900210A EE9900210A EE9900210A EE 9900210 A EE9900210 A EE 9900210A EE P199900210 A EEP199900210 A EE P199900210A EE 9900210 A EE9900210 A EE 9900210A EE 9900210 A EE9900210 A EE 9900210A
Authority
EE
Estonia
Prior art keywords
oxytocin analogues
heptapeptide
heptapeptide oxytocin
analogues
oxytocin
Prior art date
Application number
EEP199900210A
Other languages
English (en)
Other versions
EE03832B1 (et
Inventor
Melin Per
Nilsson Anders
Trojnar Jerzy
Aurell Carl-Johan
Riviere Pierre
Haigh Robert
Original Assignee
Ferring B.V.
Ferring Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V., Ferring Ab filed Critical Ferring B.V.
Publication of EE9900210A publication Critical patent/EE9900210A/et
Publication of EE03832B1 publication Critical patent/EE03832B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EEP199900210A 1996-11-26 1997-11-21 Heptapeptiidanaloogid EE03832B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9604341A SE9604341D0 (sv) 1996-11-26 1996-11-26 Hepta-peptide oxytocin analogue
PCT/SE1997/001968 WO1998023636A1 (en) 1996-11-26 1997-11-21 Heptapeptide oxytocin analogues

Publications (2)

Publication Number Publication Date
EE9900210A true EE9900210A (et) 1999-12-15
EE03832B1 EE03832B1 (et) 2002-08-15

Family

ID=20404757

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP199900210A EE03832B1 (et) 1996-11-26 1997-11-21 Heptapeptiidanaloogid

Country Status (34)

Country Link
US (1) US6143722A (et)
EP (1) EP0938496B1 (et)
JP (1) JP3405460B2 (et)
KR (1) KR100463132B1 (et)
CN (1) CN1129606C (et)
AR (1) AR008531A1 (et)
AT (1) ATE242264T1 (et)
AU (1) AU713424B2 (et)
BR (1) BR9713366B1 (et)
CA (1) CA2272990C (et)
CZ (1) CZ299532B6 (et)
DE (1) DE69722651T2 (et)
DK (1) DK0938496T3 (et)
EE (1) EE03832B1 (et)
ES (1) ES2203823T3 (et)
HR (1) HRP970630B1 (et)
HU (1) HU228568B1 (et)
IL (1) IL129519A (et)
LT (1) LT4650B (et)
LV (1) LV12350B (et)
MY (1) MY125555A (et)
NO (1) NO321380B1 (et)
NZ (1) NZ336445A (et)
PL (1) PL189292B1 (et)
PT (1) PT938496E (et)
RO (1) RO120772B1 (et)
RU (1) RU2180668C2 (et)
SE (1) SE9604341D0 (et)
SI (1) SI20026B (et)
SK (1) SK283800B6 (et)
TR (1) TR199901028T2 (et)
UA (1) UA54459C2 (et)
WO (1) WO1998023636A1 (et)
ZA (1) ZA9710518B (et)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US6476072B1 (en) * 2000-11-21 2002-11-05 Arthur Vanmoor Method of treating menstrual pain by enhancing the effectiveness of the human immune system
ATE346084T1 (de) * 2002-02-27 2006-12-15 Ferring Bv Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga
WO2003093816A2 (en) * 2002-05-02 2003-11-13 Bayer Healtchare Ag Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
GB0210397D0 (en) 2002-05-07 2002-06-12 Ferring Bv Pharmaceutical formulations
UA76639C2 (uk) * 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
SI1500390T1 (sl) * 2003-07-25 2006-02-28 Ferring Bv Farmacevtski dezmopresinski sestavek kot trdna dozirna oblika in postopek za njegovo pripravo
PT1530967E (pt) * 2003-11-13 2006-09-29 Ferring Bv Embalagem blister e uma forma de dosagem solida que compreende desmopressina.
EP1555029A1 (en) 2004-01-19 2005-07-20 Ferring B.V. Use of substances having oxytocin antagonistic properties for the preparation of a medicament for treating hypertension
US20060171909A1 (en) * 2005-02-03 2006-08-03 The Procter & Gamble Company Cosmetic compositions comprising colorants with low free dye
SE0600482L (sv) * 2006-03-02 2006-11-14 Ferring Int Ct Sa Farmaceutisk sammansättning innefattande desmopressin, kiseldioxid och stärkelse
KR101522747B1 (ko) 2007-08-06 2015-05-26 알레간 인코포레이티드 데스모프레신 약물 전달을 위한 방법 및 장치
MX2010010743A (es) * 2008-03-31 2010-11-04 Ferring Bv Analogos de oxitocina.
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
HUE041370T2 (hu) 2008-05-21 2019-05-28 Ferring Bv Orodiszperzibilis dezmopresszin az alvás noktúria által meg nem zavart kezdeti szakaszának megnövelésére
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
MX2013000543A (es) 2010-07-15 2013-10-28 Oleg Iliich Epshtein Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
JO3400B1 (ar) * 2010-09-30 2019-10-20 Ferring Bv مركب صيدلاني من كاربيتوسين
EP2684888B1 (en) 2011-03-09 2019-05-15 Jitsubo Co., Ltd. Novel cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
CN102875650B (zh) * 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法
US9365615B2 (en) 2013-09-09 2016-06-14 Jitsubo Co., Ltd. Cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
EP3501533B1 (en) * 2014-12-22 2025-07-09 Ferring B.V. Obe001 for use in the treatment in implantation and pregnancy in women undergoing assisted reproductive technologies
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
JP2018535946A (ja) 2015-10-06 2018-12-06 フェリング・ベー・フェー バルシバン及びその中間体を作製する新規の方法
WO2017118639A1 (en) 2016-01-04 2017-07-13 ObsEva S.A. Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
US20190247361A1 (en) 2016-07-21 2019-08-15 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
EP4025207A1 (en) 2019-09-03 2022-07-13 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
CA3167121A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ279654B6 (cs) * 1987-12-21 1995-05-17 Sandoz Ag Způsob výroby cyklosporinu A
US5373089A (en) * 1988-09-02 1994-12-13 Northwestern University Oxytocin antagonist
CA2036973A1 (en) * 1990-02-27 1991-08-28 Mark G. Bock Cyclic hexapeptide oxytocin antagonists
SE9002384D0 (sv) * 1990-07-09 1990-07-09 Ferring Ab Derivat av baklobshormoner
DE4022247A1 (de) * 1990-07-12 1992-01-16 Hoechst Ag Verfahren zur extraktiven abtrennung von 2-alkylthio-5-phenylpyrimidinen aus ihren reaktionsgemischen
SE501678C2 (sv) * 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE523819C2 (sv) 1994-01-27 2004-05-18 Per-Ingvar Nilsson Accelerationsmunstycke samt metod för dess användning
SE9400918L (sv) 1994-03-18 1995-09-19 Anne Fjellstad Paulsen Stabiliserad komposition för oral administrering av peptider
SE503085C2 (sv) 1995-01-25 1996-03-25 Valeo Engine Cooling Ab Värmeväxlartank med ändstycken, förfarande för framställning av en sådan tank, samt värmeväxlare försedd med en sådan

Also Published As

Publication number Publication date
DK0938496T3 (da) 2003-10-06
EP0938496B1 (en) 2003-06-04
IL129519A (en) 2004-09-27
AU5142998A (en) 1998-06-22
RO120772B1 (ro) 2006-07-28
NO992532D0 (no) 1999-05-26
LV12350B (en) 1999-11-20
SE9604341D0 (sv) 1996-11-26
KR100463132B1 (ko) 2004-12-23
LT99052A (en) 2000-01-25
ZA9710518B (en) 1998-06-10
DE69722651D1 (en) 2003-07-10
EE03832B1 (et) 2002-08-15
LT4650B (lt) 2000-04-25
PL189292B1 (pl) 2005-07-29
CA2272990C (en) 2002-11-19
SI20026A (sl) 2000-02-29
HK1022481A1 (en) 2000-08-11
AR008531A1 (es) 2000-01-19
EP0938496A1 (en) 1999-09-01
SK283800B6 (sk) 2004-02-03
TR199901028T2 (xx) 1999-07-21
JP3405460B2 (ja) 2003-05-12
ATE242264T1 (de) 2003-06-15
UA54459C2 (uk) 2003-03-17
WO1998023636A1 (en) 1998-06-04
ES2203823T3 (es) 2004-04-16
HRP970630B1 (en) 2002-04-30
NZ336445A (en) 2000-06-23
NO321380B1 (no) 2006-05-02
KR20000069045A (ko) 2000-11-25
CN1238781A (zh) 1999-12-15
IL129519A0 (en) 2000-02-29
JP2000507617A (ja) 2000-06-20
CZ299532B6 (cs) 2008-08-27
SK70499A3 (en) 2000-10-09
BR9713366A (pt) 2000-01-25
CZ183299A3 (cs) 2000-05-17
DE69722651T2 (de) 2004-04-08
PT938496E (pt) 2003-10-31
HUP0000577A2 (hu) 2000-11-28
HU228568B1 (en) 2013-04-29
CN1129606C (zh) 2003-12-03
BR9713366B1 (pt) 2010-05-18
LV12350A (lv) 1999-09-20
CA2272990A1 (en) 1998-06-04
HUP0000577A3 (en) 2001-02-28
US6143722A (en) 2000-11-07
HRP970630A2 (en) 1998-10-31
AU713424B2 (en) 1999-12-02
SI20026B (sl) 2000-06-30
RU2180668C2 (ru) 2002-03-20
NO992532L (no) 1999-05-26
MY125555A (en) 2006-08-30

Similar Documents

Publication Publication Date Title
EE9900210A (et) Heptapeptiid oksütotsiini analoogid
DK1042359T3 (da) k-Opioidreceptorpeptider
NL300344I1 (nl) Nucleotide-analogen
NO983069D0 (no) Inhalasjonsanordning
FI965225A7 (fi) Uusia peptidejä
FI961350A7 (fi) Hapteenimerkityt peptidit
DE59806407D1 (de) Drucktaster
NO985680L (no) Peptidderivater
EP0985372A4 (en) VACUUM CLEANER
EP0996458A4 (en) SANDRAMYCIN ANALOG
NO983849L (no) Peptidderivater
LV11747A (lv) Alfa-1-antihimotripsina analogi kuriem piemit elastazi inhibejosa aktivitate
FI970168A0 (fi) Peptidejä
DE69833023D1 (de) Luftreiniger
FI963194L (fi) Syklinen tulehduksenvastainen heptapeptidi
FI964363L (fi) Peptidejä
DE69819097D1 (de) Drucktaster
DE59803807D1 (de) Reinigungsgerät
DE69829805D1 (de) Luftreiniger
DE69715327D1 (de) Reinigungsgerät
FI950211A0 (fi) Huokosia muodostavia peptidejä Geolycosa riograndesta
DE59811930D1 (de) Drucktaster
FI960051L (fi) Difluoristatonianalogeja
KR970027220U (ko) 공기 청정기
DE59804430D1 (de) Ansaugeinrichtung

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

KB4A Valid patent at the end of a year

Effective date: 20101231